Post-earnings recap
Reported
Tue, May 12, 2026
EPS actual
$-0.48
EPS est.
$-0.60
EPS surprise
+19.46%
1-day move
-1.35%
Immunome reported a narrower-than-expected loss per share, beating expectations on EPS. However, the stock fell by 1.35% in reaction, indicating that investors may have been looking for more positive news or clearer guidance. The lack of revenue figures and management commentary may have contributed to the stock's decline.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.48 | N/A | +19.46% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.
Immunome, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other diseases using its proprietary platform. With a market cap of $3 billion, it operates in the health care sector, which is increasingly important as advancements in biotechnology continue to shape treatment options for patients.
Last quarter
In the last quarter, Immunome reported an EPS of -$2.43, significantly missing expectations. The stock reacted negatively, dropping 3.02% the following day.
EPS beat streak
0Q
EPS beat rate
38%
Avg EPS surprise
-44.87%
Avg 1-day reaction
-0.97%
Overall expectations for this quarter are cautious, given the company's recent history of missing earnings estimates. Investors are looking for signs of improvement in both EPS and revenue growth.
Bull case
If Immunome can show a smaller loss than expected and provide positive updates on its pipeline, it could signal a turnaround, boosting investor confidence.
Bear case
Continued losses and lack of revenue growth could lead to further declines in stock price, especially if the company fails to provide clear guidance.
The print will turn on these.
Q1
What will be the reported EPS for this quarter?
A smaller loss than expected could indicate progress in managing costs and improving operations, which investors will be keen to see.
Q2
What updates can management provide on product development and revenue generation?
Clear guidance on the pipeline and potential revenue streams is crucial for investor confidence and could influence stock performance.
—
Est. EPS
$-0.17
Est. Rev
$556M
Impl. Move
±11.3%
Why consensus could be wrong
The Street may be overly pessimistic about Immunome's ability to manage costs and develop its pipeline, potentially underestimating the company's progress.
Supporting evidence
The options market is pricing in a 10.49% move, suggesting expectations for volatility that may not materialize if results are better than feared.
The company's historical EPS surprises indicate that even small improvements can lead to positive stock reactions.
Key risk
If the EPS loss is significantly smaller than expected, it could challenge the current negative sentiment surrounding the stock.
Pre-commit to what would confirm each case.
This quarter's results are critical as they will reveal whether the company is making progress in its development efforts and financial health.
Bull confirmed if
A reported EPS loss of less than $2.00 would confirm the bull case, suggesting improved operational efficiency.
Bear confirmed if
An EPS loss greater than $2.50 would confirm the bear case, indicating ongoing challenges in the business.
What the market is pricing for the move.
Implied Move
±10.49%
Historical Avg
±3.4%
The options market is pricing in a significant move, indicating that investors anticipate volatility around the earnings report.
Options are pricing ±7.0% while IMNM has averaged ±3.4% over the last 8 prints — setup is pricing rich.
ATM IV
0.9%
30d HV
38.8%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 1 of 6 (17%)
This setup has occurred 30 times across Health Care in the last 2 years. 5 of 6 (83%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 3.6%, with a raw directional average of -2.0% (modestly negative historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Immunome beats expectations, history suggests the stock could rise by an average of 1.42%, confirming a positive trend.
In line / cautious
If results are in line with expectations but lack strong guidance, the stock may see muted movement as investors reassess their outlook.
Miss
If the company misses expectations, history suggests a potential decline of around 3.42%, reflecting ongoing investor concerns.
The lines on the call that would change the story.